Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01169311 · ClinicalTrials.gov registry record · NA
Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure
A NA study, sponsored by Medtronic - MITG.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT01169311 is a NA study that has completed, run by Medtronic - MITG. The registered enrollment target is 27 participants.
The verdict
NCT01169311, a NA study, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
Trial Objectives The primary objectives of this clinical trial are to estimate the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set: overall performance defined by the successful creation of a normal staple line safety as measured by the 30 day incidence of adverse events.
Interventions
- DEVICE Hemorrhoidopexy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01169311
The ClinicalTrials.gov registry entry for NCT01169311 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hemorrhoidopexy is the first listed.
NCT01169311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01169311 about?
NCT01169311 is a clinical study titled "Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure". Trial Objectives The primary objectives of this clinical trial are to estimate the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set: overall performance defined by the successful creation of a normal staple line safety as measured by the 30 day incidence of adverse events.
What is the current status of trial NCT01169311?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2010-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01169311?
The interventions under investigation include: Hemorrhoidopexy (DEVICE).
Who is sponsoring clinical trial NCT01169311?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.